One‐pot synthesis and biological evaluation of novel 4‐[3‐fluoro‐4‐(morpholin‐4‐yl)]phenyl‐1H‐1,2,3‐triazole derivatives as potent antibacterial and anticancer agents

Abstract

AbstractIn search of better antibacterial and anticancer agents, a series of novel 4‐[3‐fluoro‐4‐(morpholin‐4‐yl)]phenyl‐1H‐1,2,3‐triazole derivatives were synthesized (6a‐l and 8a‐j) by using 3‐fluoro‐4‐morpholinoaniline, alkyne, and triflyl azide via an in situ generated 4‐(4‐azido‐2‐fluorophenyl)morpholine and evaluated for their antibacterial and anticancer activity in vitro. Antibacterial activity against three G+ bacterial strains and anticancer activity against breast cancer cell line (MCF‐7) and cervical carcinoma cell line (HeLa) was evaluated. Among all the tested compounds, 6h, 6i, and 8b exhibited potent antibacterial activity against tested gram‐positive bacterial strains. The anticancer activity screening results of 8f, 8h, and 8i exhibited potent cytotoxic activity against two cancer cell lines with IC50 values nearer to the standard drug, doxorubicin. The remaining compounds have shown good to moderate activity against the tested cell lines. On the basis of the results obtained, a structure‐activity relationship (SAR) is discussed.